🚨 Xenon Pharmaceuticals ($XENE) just had its worst trading day since 2017, and the analyst community is split on how bad this actually is

🚨 Xenon Pharmaceuticals ($XENE) just had its worst trading day since 2017, and the analyst community is split on how bad this actually is What happened: Xenon voluntarily paused new patient enrollment in its ongoing Phase 3 trials of azetukalner (its lead Kv7 potassium channel opener) for major depressive disorder (X-NOVA) and bipolar depression (X-CEED), after neuropsychiatric adverse events emerged in the studies. This is separate from azetukalner's epilepsy program (X-TOLE2), which had previously posted strong Phase 3 data and remains on track for an NDA filing. Analyst reactions were notably divided: 📉 Deutsche Bank (David Hoang): Downgraded to Hold from Buy, slashing the price target to $46 from $90 — the most bearish reaction of the group. 📉 Needham: Cut PT to $60 from $78, but kept a Buy rating, citing the enrollment pause specifically as the reason for the reduction. 📉 Wells Fargo (Benjamin Burnett): Trimmed PT to $64 from $69, maintained Overweight. 📉 Baird: Lowered PT to $90 from $97, kept Outperform — the most confident holdout, implying meaningful upside still seen even after the news. 🔄 Citi (Samantha Semenkow): Took a different angle entirely — viewing Xenon's pause as a competitive positive for Biohaven ($BHVN), whose own neuropsychiatric pipeline could benefit from reduced competition. Market reaction: The stock fell as much as -26.14% in extended hours per CNBC, with Barron's calling it Xenon's worst day since 2017. Even after the plunge, the stock remains up over 27% year-to-date, reflecting how much value had been built up on azetukalner's broader neuropsychiatric expansion thesis before this setback. Bottom line: This is a real, negative company-specific catalyst — but the fact that most sell-side firms maintained Buy/Overweight/Outperform ratings (just at lower price targets) suggests the epilepsy franchise and overall pipeline value are still seen as intact. The MDD/BPD neuropsychiatric expansion, however, is now facing a genuine safety-related setback that will need much closer scrutiny. Humble Trader | Gemini Trading 慢慢買。分批佈局。讓時間站在你這邊。🙏 \[NOT FINANCIAL ADVICE, DYOR!\] https://preview.redd.it/slu1avwwq9qh1.png?width=225&format=png&auto=webp&s=26f11313c42efdf016a72b82bf3a2b83302f5afc https://preview.redd.it/mltfjyf5r9qh1.png?width=1174&format=png&auto=webp&s=4e3ebf1c0494824f17102b3673d0aa9e9614607a https://preview.redd.it/oopiy4wdr9qh1.png?width=996&format=png&auto=webp&s=cf8ca671c400ade1625efcd85deb24a9f25ce1da